Opinion|Videos|August 8, 2024 (Updated: July 23, 2024)
Managing ILD and Pneumonitis Risk From ADCs
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the most common toxicities associated with ADCs? Which are most concerning for physicians? For patients?
- What toxicities are of greatest concern for patients withgynecologic, GI, Lung ,and GU cancers?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
AI-assisted scoping review of code sharing in clinical prediction model research
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
Advertisement
Advertisement